Nature Communications · 2021 · 114 citations · 20 references
PharmacyChemistryMedicinal ChemistryDrug DesignDrug DiscoveryStructure-activity RelationshipsHit-to-lead OptimizationLead Compound DesignLead DiscoveryLigand BindingLigand-based DesignProtein-ligand DockingAntiviral Structure-activity RelationshipsProtease InhibitorsProtein-protein Interaction Inhibitor DiscoveryStructure-based Lead DiscoveryStructure-based Lead IdentificationStructure-guided Lead Discovery
We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
20
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang et al. · Nature · 2020 · 23.3K citations · Full text
Remdesivir for the Treatment of Covid-19 — Final Report
John H. Beigel, Kay M Tomashek, Lori E. Dodd et al. · New England Journal of Medicine · 2020 · 7.7K citations · Full text